Individual dosing of ASA prophylaxis by controlling platelet aggregation

Area of Science:

• Cardiology
• Pharmacology
• Hematology

Background:

• Acetylsalicylic acid is a cornerstone in cardiovascular disease prevention.
• Individual patient response to acetylsalicylic acid can vary significantly.
• Optimizing dosage is crucial for effective treatment and minimizing risks.

Purpose of the Study:

• To evaluate ex vivo platelet aggregation as a method for determining optimal individual acetylsalicylic acid dosage.
• To assess the effectiveness of different acetylsalicylic acid doses in inhibiting platelet aggregation in cardiovascular patients.

Main Methods:

• Ex vivo platelet aggregation testing using arachidonic acid induction.
• Analysis of platelet-rich plasma from 108 cardiovascular disease patients.
• Determination of individual acetylsalicylic acid doses required for near-complete platelet aggregation inhibition.

Main Results:

• A 30 mg/day dose was sufficient for 40% of patients.
• 50% of patients required 100 mg/day.
• 10% of patients needed 300-500 mg/day for near-complete inhibition, indicating non-response to standard doses.

Conclusions:

• Ex vivo platelet aggregation is a practical method for tailoring acetylsalicylic acid therapy.
• Routine testing can identify patients requiring higher doses or alternative treatments.
• Standard 100 mg/day acetylsalicylic acid dosing leaves 10% of cardiovascular patients undertreated.